GODAVARIB

- Godavari Biorefineries Limited received a patent from the Mexican Patent Office for the invention titled 'USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS'. - The invention relates to the use of compounds for inhibiting V-ATPase activity in cells and manufacturing medicaments for treating viral infections.

- Shareholders approved the re-appointment of Dr. Raman Ramchandran as Director liable to retire by rotation. - Re-appointed Mr. Suhas Godage as Director liable to retire by rotation and as Whole-time Director (Executive Director - Works-Sakarwadi) w.e.f. April 1, 2027. - Re-appointed Mr. Samir S. Somaiya as Managing Director w.e.f. April 1, 2027. - Appointed Mr. Dinesh Sharma as Director and Whole-time Director (Executive Director - Works-Sameerwadi) for 3 years.

- Trading window for dealing in securities of the company will close from October 01, 2026. - Closure remains effective until 48 hours post declaration of unaudited financial results for the quarter and half-year ended September 30, 2026. - Applies to Directors, KMP, designated persons, and their immediate relatives.

- Concall Schedule - Concall Date: September 29, 2026 - Concall Time: Not explicitly stated, but described as a Virtual Group Meeting.

- Godavari Biorefineries Ltd has been granted a patent by the Chinese Patent Office. - The patent is titled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS." - The invention involves compounds for inhibiting V-ATPase activity in cells and their use in medicaments for treating viral infections. - The patent was granted on September 15, 2026.

- Godavari Biorefineries Ltd. has been granted a European Patent for 'A Biofiller for Rubber Reinforcement'. - The invention provides an efficient, economic, biodegradable, and eco-friendly biofiller designed to partially replace conventional carbon black in rubber products, offering performance, cost savings, and environmental benefits.

New Filing detected. See link for details.

- Godavari Biorefineries Ltd received a show-cause notice on August 28, 2026, from the Commercial Tax Officer (Enforcement), Jamkhandi, Karnataka. - The notice concerns short payment/non-payment/ineligible input tax credit for the tax period 2022-23. - Total demand claimed is approx. ₹18.12 Crores, comprising ₹10.57 Crores GST, ₹6.50 Crores interest, and ₹1.05 Crores penalty. - The company is examining the notice and will take appropriate legal steps.

- Godavari Biorefineries Ltd received a Show Cause Notice from the Assistant Commissioner of Central GST, Audit, Belgavi, Karnataka, dated August 21, 2026. - The notice is regarding alleged non-payment of GST on the supply of Extra Neutral Alcohol (ENA) for the period 2021-22 to October 2024. - The total GST demand is approximately ₹17.02 Crores (CGST ₹8.51 Cr, SGST ₹8.51 Cr). - The Company is currently examining the notice and plans to take appropriate legal steps, including filing replies/appeals.

- Q1 FY27 profitability was impacted by elevated inventory carrying costs and higher raw material prices, particularly in the integrated sugar, cogeneration, and ethanol segment which remained under pressure. - The bio-based chemicals business delivered strong performance, with management planning a further INR 25 crore investment in debottlenecking, aiming for quarterly business of INR 240 crore post-completion by early FY28. - Company commissioned a 200 kilolitres per day grain-based distillery, increasing total capacity to 800 kilolitres per day, and is exploring adding 160 kilolitres per day maize preparation capacity for feedstock flexibility. - Secured a Japanese patent for a novel anticancer molecule and an Indian patent for branched alcohols; preliminary efficacy trials for the anticancer molecule are expected to commence from Q3 FY27. - DME pilot trial results are anticipated by March 2027, and the company is exploring opportunities in bio-butanol and Compressed Biogas (CBG). - Management expects to maintain similar debt levels, without major changes to the debt-equity structure.

- Godavari Biorefineries Ltd announced the grant of a European patent for 'PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME'. - The patent relates to anti-cancer compounds designed to enhance solubility and bioavailability, with applications in treating various cancers.

- Concall Schedule - Concall Date: August 12, 2026 - Event: Emkay Confluence 2026 - India: Full Throttle Ahead (Physical Group Meeting)

- Audio recording of the earnings conference call for Q1 FY27 has been uploaded on the company's website. - The filing date is August 07, 2026.

- Q1 FY27 Total Income ₹559.9 Cr (▲4.9% YoY vs Q1 FY26). - Bio-based Chemicals EBITDA grew ▲53% YoY, with margin expanding to 11.4% from 8.9% in Q1 FY26. - Commissioned new 200 KLPD corn/grain-based distillery, increasing total distillery capacity to 800 KLPD. - Granted Japanese patent and filed CDSCO application for a novel anti-cancer molecule.

- Consolidated Revenue ₹559.9 Cr vs ₹534.0 Cr (▲4.9% YoY) - EBITDA ₹2.6 Cr vs ₹6.5 Cr (▼60.0% YoY) - PAT loss increased to ₹(19.3) Cr from ₹(16.0) Cr YoY - EBITDA Margin 0.46% vs 1.22% (▼76 bps) - Commissioned 200 KLPD grain-based distillery, increasing total ethanol capacity to 800 KLPD. - Secured Japanese patent for an anti-cancer molecule and filed CDSCO application for preliminary efficacy trials.

- Consolidated Revenue ₹557.88 Cr vs ₹533.24 Cr (▲4.62% YoY) - EBITDA ₹0.52 Cr vs ₹5.76 Cr (▼90.95% YoY) - PAT (Loss) ₹19.32 Cr vs (Loss) ₹16.02 Cr (Loss increased ▲20.62% YoY) - EBITDA Margin 0.09% vs 1.08% (▼99bps) - Board approved the 71st Annual General Meeting (AGM) to be held on September 28, 2026, via Video Conferencing.

- Concall Schedule for Q1 FY27 Earnings - Concall Date: Friday, August 7, 2026 - Concall Time: 11:00 AM IST

- Re-appointment of Mr. Nitin Mehta as an Independent Director for a term of 5 years, effective July 1, 2026. - Re-appointment of Dr. Sangeeta Srivastava as a Whole Time Director (Executive Director) for a term of 3 years, effective August 1, 2026.

- Results of the Postal Ballot for resolutions dated May 22, 2026, were declared on June 29, 2026. - Re-appointment of Mr. Nitin Mehta as an Independent Director was approved with 99.9928% votes in favour. - Re-appointment of Dr. Sangeeta Srivastava as a Whole Time Director was approved with 99.9931% votes in favour. - Both resolutions passed with the requisite majority.

- Godavari Biorefineries Ltd commenced operations of its corn/grain-based distillery at Sameerwadi Unit on June 29, 2026. - The new capacity addition is 200 KLPD, with an approximate investment of ₹130 Cr, financed through internal accruals and debt. - This provides dual-feedstock capability for resilient ethanol production, supporting India's ethanol blending program.

- Intimation of the closure of the trading window for dealing in the company's securities. - The trading window will be closed from July 1, 2026, until 48 hours after the declaration of financial results for the quarter ending June 30, 2026. - This is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

- Godavari Biorefineries Ltd received a patent grant from the Japanese Patent Office for "5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER". - The patent covers compounds with strong inhibitory effects on cancer and cancer stem cells, showing efficacy against breast and prostate cancer. - Patent Number: 7869786. Registered on: May 26, 2026.